Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled trial of BI 456906 (Survodutide) in NASH with fibrosis
jRCT2051210037Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2021
- Modality
- Peptides
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Survodutide (BI 456906) with Placebo (2 arms). Primary endpoint: Histological improvement of NASH and fibrosis at 48 weeks. Started Jul 2021; status: completed.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2051210037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210037.